Abstract
A specific inhibitor of the mitogen-activated protein kinase (MAPK or ERK) pathway is introduced as a new member in the growing search for cytostatic drugs that block tumor growth (pages 810–816).
This is a preview of subscription content, log in via an institution to check access.
References
Sebolt- Leopold, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810–816 (1999).
Lewis, T.S., Shapiro, P.S. & Ahn, N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49–139 (1998).
Cowley, S., Paterson, H., Kemp, P. & Marshall, C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841–852 (1994).
Mansour, S.J. et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966– 970 (1994).
Webb, C.P., Van Aelst, L., Wigler, M.H. & Vande Woude G.F. Signaling pathways in ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA 95, 8773– 8778 (1998).
Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. & Saltiel, A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686–7689 (1995).
Okazaki, K. & Sagata, N. MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos. Oncogene 10, 1149–1157 (1995).
Nishio, K. et al. Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells. Int. J. Oncol. 14, 461–469 (1999).
Duesbery, N. and Vande Woude, G.F. Anthrax lethal factor causes proteolytic inactivation of MAP-Kinase-Kinase. Lett. Appl. Microbiol. (in the press 1999).
Hoshino, R. et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813–822 (1999).
Salh, B. et al Differential cyclin-dependent kinase expression and activation in human colon cancer. Anticancer Res. 19, 741–748 (1999).
Sivaraman, V.S., Wang, H., Nuovo, G.J., & Malbon, C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99, 1478–1483 (1997).
Mandell, J.W., Hussaini, I.M., Zecevic, M., Weber, M.J. & Vandenberg, S.R. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol. 153, 1411–1423 (1998).
Duesbery, N.S. et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734– 737 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Duesbery, N., Webb, C. & Vande Woude, G. MEK Wars, a new front in the battle against cancer. Nat Med 5, 736–737 (1999). https://doi.org/10.1038/10457
Issue Date:
DOI: https://doi.org/10.1038/10457
- Springer Nature America, Inc.
This article is cited by
-
Utility of Immunohistochemistry Markers CK19, Gal-3, HBME-1 and Their Combinations for Differential Diagnosis of Thyroid Diseases
Indian Journal of Surgery (2023)
-
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells
Leukemia (2005)
-
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis
Leukemia (2004)
-
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts
Leukemia (2003)
-
Direct integrin αvβ6-ERK binding: implications for tumour growth
Oncogene (2002)